Newer PDE5 inhibitors: avanafil, udenafil, mirodenafil and lodenafil

AI-generated editorial illustration. Packaging varies by market; fine print is approximate.

Avanafil, udenafil, mirodenafil and lodenafil bring different practical and research questions to the PDE5 family. “Newer” does not establish superiority, and the markets documented here should not be reduced to one regulator’s database.

What is distinctive in the evidence?

Ingredient	Product connection	Useful evidence question
Avanafil	Stendra, Spedra, Avana	What did “successful within fifteen minutes” actually measure?
Udenafil	Zydena, Zudena	What can selected hypertension and blood-exposure studies tell us?
Mirodenafil	Mvix tablet/film context	Did the film trial compare speed with an ordinary tablet?
Lodenafil	Helleva	Does unusual prodrug chemistry establish a clinical advantage?

The expanded ingredient pages answer those questions using the primary studies. Their endpoints differ, so numbers from separate trials should not be placed in a league table as though the same patients and conditions were compared.

Update the geographic picture carefully

Stendra and Spedra have specific US and EU reference records. Dong-A ST’s international product table also lists Zydena exports to Ukraine, Malaysia and Jordan, and a company announcement records a historical Russian launch. A blanket “South Korea only” statement misses that evidence.

For Helleva, the Brazilian professional leaflet provides a product and company-role record. For Mvix, research and historical development evidence do not independently settle the current Korean holder of every presentation. These different confidence levels should remain visible rather than turned into sweeping worldwide approval claims.

Read positive results with their comparator

Avanafil’s early-onset study used placebo, not all familiar ED alternatives. Mirodenafil’s film trial did not directly compare an ordinary tablet. Lodenafil’s laboratory enzyme findings are not a patient-level superiority result. Udenafil’s hypertension trial involved selected men already on blood-pressure treatment, not every cardiovascular condition.

Those limits do not erase the positive findings. They explain which clinical questions the studies actually answer and what further evidence a comparison would need.

Bring the product back into the decision

Original-brand research is not a trial of every supplier’s product containing the same ingredient. A current company listing, a national authorization and the supplied leaflet answer different identity and use questions. Read medicine records worldwide for that distinction and the interaction guide before prioritizing novelty or onset.

Sources

17 sources

Checked October 4, 2026.